MedDataX Logo

Chlamydia and Mycoplasma in Coronary Artery Disease

NCT ID: NCT00561028

Last Updated: 2007-11-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

138 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-03-31

Study Completion Date

2004-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To test the association between anti-Chlamydia serum titers and anti-Mycoplasma antibodies with Acute Coronary Syndromes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

One hundred and twenty-six patients were divided into 4 groups: Acute Coronary Syndrome with ST-elevation, Non-ST-elevation, stable coronary artery disease, and individuals without coronary disease. Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured at baseline and after 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis Coronary Artery Disease Chlamydia Infections Mycoplasma Infections

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Atherosclerosis Coronary artery disease Chlamydia pneumoniae Mycoplasma pneumoniae

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

ST-elevation acute myocardial infarction.

blood sample analysis - mycoplasma and chlamydia antibodies

Intervention Type OTHER

Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).

2

high-risk unstable angina or non-ST-elevation myocardial infarction.

blood sample analysis - mycoplasma and chlamydia antibodies

Intervention Type OTHER

Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).

3

known coronary artery disease, either asymptomatic or with stable angina.

blood sample analysis - mycoplasma and chlamydia antibodies

Intervention Type OTHER

Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).

4

blood donors without known coronary artery disease.

blood sample analysis - mycoplasma and chlamydia antibodies

Intervention Type OTHER

Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample analysis - mycoplasma and chlamydia antibodies

Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 yrs
* Males and females
* Agreed to sign the informed consent

Exclusion Criteria

* Refusal to sign the informed consent
* Follow-up not possible
* For the "acute" groups, time between the pain beginning and randomization \>24 hours
* Active infections
* Use of antimicrobial agents within the last 30 days
* End-stage diseases with life expectancy \<6 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Sao Paulo

OTHER

Sponsor Role collaborator

Hospital de Base

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jose C Nicolau, MD, pHD

Role: STUDY_DIRECTOR

University of Sao Paulo

References

Explore related publications, articles, or registry entries linked to this study.

Maia IL, Nicolau JC, Machado MN, Maia LN, Takakura IT, Rocha PR, Cordeiro JA, Ramires JA. Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae in different forms of coronary disease. Arq Bras Cardiol. 2009 Jun;92(6):405-11, 422-8, 439-45. doi: 10.1590/s0066-782x2009000600005. English, Multiple languages.

Reference Type DERIVED
PMID: 19629306 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

885/02

Identifier Type: -

Identifier Source: secondary_id

5105/2001

Identifier Type: -

Identifier Source: org_study_id